SHANGHAI JUNSHI BIO YC1 Asset Resilience Ratio
SHANGHAI JUNSHI BIO YC1 asset resilience ratio. SHANGHAI JUNSHI BIO YC1 (8SJ) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 8SJ defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of SHANGHAI JUNSHI BIO YC1 (2024–2025)
Asset resilience ratio of SHANGHAI JUNSHI BIO YC1 from 2024 to 2025. This chart shows how SHANGHAI JUNSHI BIO YC1's Asset Resilience Ratio has changed over time. Read total liabilities of SHANGHAI JUNSHI BIO YC1 for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SHANGHAI JUNSHI BIO YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 8SJ total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €600.78 Million | 4.85% |
| Total Liquid Assets | €600.78 Million | 4.85% |
Asset Resilience Insights
- Limited Liquidity: SHANGHAI JUNSHI BIO YC1 maintains only 4.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SHANGHAI JUNSHI BIO YC1 Industry Peers by Asset Resilience Ratio
Compare SHANGHAI JUNSHI BIO YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
SHANGHAI JUNSHI BIO YC1 Asset Resilience Ratio by Year (2024–2025)
SHANGHAI JUNSHI BIO YC1 asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for SHANGHAI JUNSHI BIO YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.85% | €600.78 Million ≈ $702.38 Million |
€12.40 Billion ≈ $14.50 Billion |
+0.86pp |
| 2024-12-31 | 3.99% | €430.51 Million ≈ $503.31 Million |
€10.80 Billion ≈ $12.63 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more